Gary M Woods1, Ruchika Sharma2, Susan Creary3, Sarah O'Brien3, Joseph Stanek4, Kan Hor5, Jennifer Young6, Amy L Dunn3, Riten Kumar7. 1. Division of Pediatric Hematology/Oncology, Children's Hospital of the King's Daughters, Norfolk, VA. 2. Division of Pediatric Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI. 3. Division of Pediatric Hematology/Oncology, Nationwide Children's Hospital, Columbus, OH; Department of Pediatrics, The Ohio State University, Columbus, OH. 4. Division of Biostatistics, Nationwide Children's Hospital, Columbus, OH. 5. Department of Pediatrics, The Ohio State University, Columbus, OH; Division of Pediatric Cardiology, Nationwide Children's Hospital, Columbus, OH. 6. Division of Pediatric Hematology/Oncology, Nationwide Children's Hospital, Columbus, OH. 7. Division of Pediatric Hematology/Oncology, Nationwide Children's Hospital, Columbus, OH; Department of Pediatrics, The Ohio State University, Columbus, OH. Electronic address: riten.kumar@nationwidechildrens.org.
Abstract
OBJECTIVES: To describe the cumulative incidence of venous thromboembolism (VTE) in children with sickle cell disease (SCD) followed at a single institution and report on the risk factors associated with VTE development. STUDY DESIGN: Charts for all patients with SCD, aged 0-21 years, followed at Nationwide Children's Hospital over a 6-year period (January 1, 2009, to January 31, 2015) were reviewed. Data on VTE diagnosis, sex, body mass index/weight-for-length, SCD genotype, SCD clinical complications, central venous catheter (CVC) placement, and thrombophilia testing were collected. RESULTS: Cumulative incidence of VTE in children with SCD followed at a single tertiary care institution was found to be 2.9% (12/414). Nine of the 12 VTE were CVC-associated. On univariate analysis, hemoglobin SS genotype (OR 10.7, 95% CI 1.4-83.5), CVC presence (OR 34.4, 95% CI 8.9-134.6), central nervous system vasculopathy (OR 19.4, 95% CI 5.6-63.4), chronic transfusion therapy (OR 30.6, 95% CI 8.9-122.2), and older age (P = .03) were associated with VTE. However, presence of CVC was the only independent risk factor identified on multivariable logistic regression analysis (OR 33.8, 95% CI 8.7-130.9). CONCLUSION: In our institution, nearly 3% of children with SCD had a history of VTE. CVC is an independent predictor of VTE in children with SCD.
OBJECTIVES: To describe the cumulative incidence of venous thromboembolism (VTE) in children with sickle cell disease (SCD) followed at a single institution and report on the risk factors associated with VTE development. STUDY DESIGN: Charts for all patients with SCD, aged 0-21 years, followed at Nationwide Children's Hospital over a 6-year period (January 1, 2009, to January 31, 2015) were reviewed. Data on VTE diagnosis, sex, body mass index/weight-for-length, SCD genotype, SCD clinical complications, central venous catheter (CVC) placement, and thrombophilia testing were collected. RESULTS: Cumulative incidence of VTE in children with SCD followed at a single tertiary care institution was found to be 2.9% (12/414). Nine of the 12 VTE were CVC-associated. On univariate analysis, hemoglobin SS genotype (OR 10.7, 95% CI 1.4-83.5), CVC presence (OR 34.4, 95% CI 8.9-134.6), central nervous system vasculopathy (OR 19.4, 95% CI 5.6-63.4), chronic transfusion therapy (OR 30.6, 95% CI 8.9-122.2), and older age (P = .03) were associated with VTE. However, presence of CVC was the only independent risk factor identified on multivariable logistic regression analysis (OR 33.8, 95% CI 8.7-130.9). CONCLUSION: In our institution, nearly 3% of children with SCD had a history of VTE. CVC is an independent predictor of VTE in children with SCD.
Authors: Andrew Srisuwananukorn; Rasha Raslan; Xu Zhang; Binal N Shah; Jin Han; Michel Gowhari; Robert E Molokie; Victor R Gordeuk; Santosh L Saraf Journal: Blood Adv Date: 2020-05-12
Authors: Riten Kumar; Katherine Harsh; Surbhi Saini; Sarah H O'Brien; Joseph Stanek; Patrick Warren; Jean Giver; Michael R Go; Bryce A Kerlin Journal: J Pediatr Date: 2018-12-07 Impact factor: 4.406
Authors: Robert I Liem; Sophie Lanzkron; Thomas D Coates; Laura DeCastro; Ankit A Desai; Kenneth I Ataga; Robyn T Cohen; Johnson Haynes; Ifeyinwa Osunkwo; Jeffrey D Lebensburger; James P Lash; Theodore Wun; Madeleine Verhovsek; Elodie Ontala; Rae Blaylark; Fares Alahdab; Abdulrahman Katabi; Reem A Mustafa Journal: Blood Adv Date: 2019-12-10
Authors: Hanne Stotesbury; Jamie M Kawadler; Patrick W Hales; Dawn E Saunders; Christopher A Clark; Fenella J Kirkham Journal: Front Neurol Date: 2019-08-13 Impact factor: 4.003
Authors: Salam Alkindi; Anwaar R Al-Ghadani; Samah R Al-Zeheimi; Said Y Alkindi; Naglaa Fawaz; Samir K Ballas; Anil V Pathare Journal: J Int Med Res Date: 2021-12 Impact factor: 1.671
Authors: Syeda Rahman; Andrew Srisuwananukorn; Robert E Molokie; Michel Gowhari; Franklin Njoku; Faiz Ahmed Hussain; James Lee; Edith A Nutescu; Victor R Gordeuk; Santosh L Saraf; Jin Han Journal: Res Pract Thromb Haemost Date: 2021-05-27